28 September 2022, 2:57 AM |The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared to a placebo, meeting the study's main goal, and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment.
Shares of Biogen and Eisai were halted, but shares of Eli Lilly & Co, which is also developing an Alzheimer’s drug, were up 6.7% in after hours trade. The company said it will also seek authorization in Japan and Europe during its current fiscal year, ending March 31. The trial also tracked the rate of micro hemorrhages in the brain, which occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group.
I know we all probably might have heard about Bitcoin but don't know how it works, I tried it in a week ago by a man who recommended me to Samantha_M078 on Twitter he guides me through and i made a return of $10500 after a week of trading, connect with her